FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321178781> ?p ?o ?g. }

• W4321178781 abstract "Cancer patients receiving chemotherapy have an increased risk of cardiovascular complications. This limits the widespread use of lifesaving therapies, often necessitating alternate lower efficacy regimens, or precluding chemotherapy entirely. Prior studies have suggested that using common cardioprotective agents may attenuate chemotherapy-induced cardiotoxicity. However, small sample sizes and conflicting outcomes have limited the clinical significance of these results.A comprehensive network meta-analysis using updated and high-quality data can provide more conclusive information to assess which drug or drug class has the most significant effect in the management of chemotherapy-induced cardiotoxicity.We performed a literature search for randomized controlled trials (RCTs) investigating the effects of cardioprotective agents in patients with chemotherapy-induced cardiotoxicity. We used established analytical tools (netmeta package in RStudio) and data extraction formats to analyze the outcome data. To obviate systematic bias in the selection and interpretation of RCTs, we employed the validated Cochrane risk-of-bias tools. Agents included were statins, aldosterone receptor antagonists (MRAs), ACEIs, ARBs, and beta-blockers. Outcomes examined were improvement in clinical and laboratory parameters of cardiac function including a decreased reduction in left ventricular ejection fraction (LVEF), clinical HF, troponin-I, and B-natriuretic peptide levels.Our study included 33 RCTs including a total of 3,285 patients. Compared to control groups, spironolactone therapy was associated with the greatest LVEF improvement (Mean difference (MD) = 12.80, [7.90; 17.70]), followed by enalapril (MD = 7.62, [5.31; 9.94]), nebivolol (MD = 7.30, [2.39; 12.21]), and statins (MD = 6.72, [3.58; 9.85]). Spironolactone was also associated with a significant reduction in troponin elevation (MD = - 0.01, [- 0.02; - 0.01]). Enalapril demonstrated the greatest BNP reduction (MD = - 49.00, [- 68.89; - 29.11]), which was followed by spironolactone (MD = - 16.00, [- 23.9; - 8.10]). Additionally, patients on enalapril had the lowest risk of developing clinical HF compared to the control population (RR = 0.05, [0.00; 0.75]).Our analysis reaffirmed that statins, MRAs, ACEIs, and beta-blockers can significantly attenuate chemotherapy-induced cardiotoxicity, while ARBs showed no significant effects. Spironolactone showed the most robust improvement of LVEF, which best supports its use among this population. Our analysis warrants future clinical studies examining the cardioprotective effects of cardiac remodeling therapy in cancer patients treated with chemotherapeutic agents." @default.
• W4321178781 created "2023-02-18" @default.
• W4321178781 creator A5005177248 @default.
• W4321178781 creator A5012321260 @default.
• W4321178781 creator A5020545610 @default.
• W4321178781 creator A5024526778 @default.
• W4321178781 creator A5027617827 @default.
• W4321178781 creator A5030890203 @default.
• W4321178781 creator A5055846167 @default.
• W4321178781 creator A5074010788 @default.
• W4321178781 creator A5076060021 @default.
• W4321178781 creator A5076375625 @default.
• W4321178781 creator A5082507728 @default.
• W4321178781 creator A5085933346 @default.
• W4321178781 date "2023-02-18" @default.
• W4321178781 modified "2023-10-10" @default.
• W4321178781 title "Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review & network meta-analysis" @default.
• W4321178781 cites W1478610489 @default.
• W4321178781 cites W1510894885 @default.
• W4321178781 cites W1617328014 @default.
• W4321178781 cites W1983953026 @default.
• W4321178781 cites W1998141986 @default.
• W4321178781 cites W2013429872 @default.
• W4321178781 cites W2017624575 @default.
• W4321178781 cites W2025087036 @default.
• W4321178781 cites W2029542561 @default.
• W4321178781 cites W2030435713 @default.
• W4321178781 cites W2049129583 @default.
• W4321178781 cites W2081964560 @default.
• W4321178781 cites W2088599677 @default.
• W4321178781 cites W2094415834 @default.
• W4321178781 cites W2099545363 @default.
• W4321178781 cites W2109634728 @default.
• W4321178781 cites W2109775164 @default.
• W4321178781 cites W2112196039 @default.
• W4321178781 cites W2120271999 @default.
• W4321178781 cites W2121050972 @default.
• W4321178781 cites W2126727347 @default.
• W4321178781 cites W2129791669 @default.
• W4321178781 cites W2133475821 @default.
• W4321178781 cites W2142877037 @default.
• W4321178781 cites W2171032801 @default.
• W4321178781 cites W2171190458 @default.
• W4321178781 cites W2271353738 @default.
• W4321178781 cites W2280485006 @default.
• W4321178781 cites W2298838354 @default.
• W4321178781 cites W2325996754 @default.
• W4321178781 cites W2470078220 @default.
• W4321178781 cites W2508734629 @default.
• W4321178781 cites W2543948044 @default.
• W4321178781 cites W2558002415 @default.
• W4321178781 cites W2577541469 @default.
• W4321178781 cites W2587882014 @default.
• W4321178781 cites W2601265260 @default.
• W4321178781 cites W2602419817 @default.
• W4321178781 cites W2789300675 @default.
• W4321178781 cites W2800400752 @default.
• W4321178781 cites W2883721214 @default.
• W4321178781 cites W2908389530 @default.
• W4321178781 cites W2939341299 @default.
• W4321178781 cites W2948656647 @default.
• W4321178781 cites W2952040438 @default.
• W4321178781 cites W2966751058 @default.
• W4321178781 cites W2978653531 @default.
• W4321178781 cites W2978795816 @default.
• W4321178781 cites W2991322788 @default.
• W4321178781 cites W2994816288 @default.
• W4321178781 cites W3012405276 @default.
• W4321178781 cites W3022903699 @default.
• W4321178781 cites W3040527195 @default.
• W4321178781 cites W3086756510 @default.
• W4321178781 cites W3134823527 @default.
• W4321178781 cites W3163516107 @default.
• W4321178781 cites W3163746674 @default.
• W4321178781 cites W3202997684 @default.
• W4321178781 cites W3206280370 @default.
• W4321178781 cites W4213217724 @default.
• W4321178781 cites W4294605240 @default.
• W4321178781 cites W631572810 @default.
• W4321178781 cites W3003865774 @default.
• W4321178781 doi "https://doi.org/10.1186/s40959-023-00159-0" @default.
• W4321178781 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36804940" @default.
• W4321178781 hasPublicationYear "2023" @default.
• W4321178781 type Work @default.
• W4321178781 citedByCount "3" @default.
• W4321178781 countsByYear W43211787812023 @default.
• W4321178781 crossrefType "journal-article" @default.
• W4321178781 hasAuthorship W4321178781A5005177248 @default.
• W4321178781 hasAuthorship W4321178781A5012321260 @default.
• W4321178781 hasAuthorship W4321178781A5020545610 @default.
• W4321178781 hasAuthorship W4321178781A5024526778 @default.
• W4321178781 hasAuthorship W4321178781A5027617827 @default.
• W4321178781 hasAuthorship W4321178781A5030890203 @default.
• W4321178781 hasAuthorship W4321178781A5055846167 @default.
• W4321178781 hasAuthorship W4321178781A5074010788 @default.
• W4321178781 hasAuthorship W4321178781A5076060021 @default.
• W4321178781 hasAuthorship W4321178781A5076375625 @default.
• W4321178781 hasAuthorship W4321178781A5082507728 @default.
• W4321178781 hasAuthorship W4321178781A5085933346 @default.
• W4321178781 hasBestOaLocation W43211787811 @default.

• next